Dapagliflozin After Transcatheter Aortic Valve Implantation
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1257 participants.
Also called NCT04696185
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 1,257 participants
- Sponsor
- Registry
-
NCT04696185
-
- Other papers using this trial's data
- Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation
- Effect of Dapagliflozin on Quality of Life of Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation
- Influence of diabetes mellitus on dapagliflozin response after transcatheter aortic valve replacement (TAVR): insights from the DAPA-TAVI trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Spain
- Registry status
- Completed
Technical summary
Registry record NCT04696185. Randomized; single masking; primary purpose treatment. Start 2021-01-27 (actual); primary completion 2024-12-29 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Dapagliflozin After Transcatheter Aortic Valve Implantation
- Acronym
- DapaTAVI
- Condition
- Aortic Stenosis
- Condition
- Transcatether Aortic Valve Implantation
- Intervention (Drug)
- Dapagliflozin 10 MG
- Lead sponsor
- Spanish Society of Cardiology
- Collaborator
- Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
Record details
- Record id
cardio:ct-nct04696185- Content hash
2d6814679ec99c002b39527ee8dc61b874bde5bf22f27523ceeb7d66bb2ae01b